Lung Cancer

Luis E. Raez, MD, provides insight into therapies available to patients with ALK-mutant non–small cell lung cancer and underscores the role of genetic testing in informing treatment decisions.

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.

The FDA has granted a final approval to pemetrexed for injection, an alternative to standard pemetrexed, for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer and for those with malignant pleural mesothelioma.

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.

Significant research advances in targeted therapy and immunotherapy within the past years have created a more personalized approach to treatment for patients with advanced non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.

The standard of care for patients with small cell lung cancer has been trapped in a period of stagnation for the past several decades.

Advancements in the prevention and treatment of patients with lung cancer have picked up momentum over the past decade and now is the time to build on that progress according to Suresh S. Ramalingam, MD, FASCO.

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

Despite a reasonable expectation that expression of HER3 and its ligand heregulin would be predictive biomarkers for HER3-targeted therapy, their usefulness in clinical trials has been hit-and-miss. Nevertheless, investigators have persevered, and new types of drugs have largely supplanted the first generation in clinical trials.

Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.

Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care for patients with advanced or metastatic treatment-naïve RET fusion–positive non–small cell lung cancer in the phase III LIBRETTO-431 (NCT04194944) trial.

The addition of dinutuximab injection to irinotecan did not improve overall survival compared with irinotecan or topotecan alone in patients with relapsed/refractory small cell lung cancer, missing the primary endpoint of the phase II/III DISTINCT trial.

Bristol-Myers Squibb has withdrawn its application in the European Union for the frontline combination of nivolumab and ipilimumab as a treatment for patients with advanced non–small cell lung cancer.

Immune checkpoint inhibitors have yielded modest improvement in small cell lung cancer (SCLC), but have already reshaped the management of this tumor type and helped open the door to the exploration of other, potentially more effective treatment approaches, according to a panel of thoracic oncology experts who discussed the treatment horizon for SCLC in a recent OncLive Peer Exchange® panel.

Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non­–small cell lung cancer.

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non

Alexander Drilon, MD, discusses the utility of brigatinib in ALK-positive non–small cell lung cancer.